Cargando…

An appropriate choice for immunotherapy in malignant pleural mesothelioma

Detalles Bibliográficos
Autor principal: Fujimoto, Nobukazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658483/
https://www.ncbi.nlm.nih.gov/pubmed/33181458
http://dx.doi.org/10.1016/j.ebiom.2020.103057
_version_ 1783608680792457216
author Fujimoto, Nobukazu
author_facet Fujimoto, Nobukazu
author_sort Fujimoto, Nobukazu
collection PubMed
description
format Online
Article
Text
id pubmed-7658483
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-76584832020-11-17 An appropriate choice for immunotherapy in malignant pleural mesothelioma Fujimoto, Nobukazu EBioMedicine Commentary Elsevier 2020-11-10 /pmc/articles/PMC7658483/ /pubmed/33181458 http://dx.doi.org/10.1016/j.ebiom.2020.103057 Text en © 2020 The Author http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Commentary
Fujimoto, Nobukazu
An appropriate choice for immunotherapy in malignant pleural mesothelioma
title An appropriate choice for immunotherapy in malignant pleural mesothelioma
title_full An appropriate choice for immunotherapy in malignant pleural mesothelioma
title_fullStr An appropriate choice for immunotherapy in malignant pleural mesothelioma
title_full_unstemmed An appropriate choice for immunotherapy in malignant pleural mesothelioma
title_short An appropriate choice for immunotherapy in malignant pleural mesothelioma
title_sort appropriate choice for immunotherapy in malignant pleural mesothelioma
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658483/
https://www.ncbi.nlm.nih.gov/pubmed/33181458
http://dx.doi.org/10.1016/j.ebiom.2020.103057
work_keys_str_mv AT fujimotonobukazu anappropriatechoiceforimmunotherapyinmalignantpleuralmesothelioma
AT fujimotonobukazu appropriatechoiceforimmunotherapyinmalignantpleuralmesothelioma